|
Impact of dose reductions on 5-year efficacy in newly diagnosed patients with chronic myeloid leukemia in chronic phase (CML-CP) from DASISION. |
|
|
Consulting or Advisory Role - Amphivena Therapeutics; ARIAD; BiolineRx; Bristol-Myers Squibb; Janssen; Novartis; Pfizer |
Research Funding - Ambit BioSciences (Inst); ARIAD (Inst); Arog (Inst); Astellas Pharma (Inst); Bristol-Myers Squibb (Inst); Celator (Inst); Celgene (Inst); Immunogen (Inst); Incyte (Inst); Novartis (Inst); Pfizer (Inst); Teva (Inst) |
|
|
Consulting or Advisory Role - ARIAD; Bristol-Myers Squibb; Novartis; Pfizer |
Research Funding - ARIAD; Bristol-Myers Squibb; Novartis; Pfizer |
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Novartis |
|
|
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); Novartis (Inst); Pfizer (Inst) |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - ARIAD; Incyte; Novartis; Pfizer |
Research Funding - Incyte; Karyopharm Therapeutics; Pfizer |
Travel, Accommodations, Expenses - ARIAD; Incyte; Pfizer |
|
|
Consulting or Advisory Role - ARIAD (Inst); Bristol-Myers Squibb (Inst); Novartis (Inst) |
Research Funding - ARIAD (Inst); Bristol-Myers Squibb (Inst); Novartis (Inst) |
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Novartis |
|
|
No Relationships to Disclose |
|
|
Employment - Bristol-Myers Squibb |
Stock and Other Ownership Interests - Bristol-Myers Squibb |
|
|
Consulting or Advisory Role - Pfizer |
Research Funding - Pfizer |